Formulary guidance and transparency from P&T to point of care


Reality Check on Acute Migraine

Market access for acute migraine treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 55% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In February 2020, the FDA approved Biohaven Pharmaceuticals’ Nurtec ODT (rimegepant) for the acute treatment of migraine in adults. The medication is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet, according to the company’s news release
  • Key Findings: Most policies require diagnosis and use of generic triptans before ergotamine, mainly due to the black box warning on ergotamine agents. Most policies require use of generic ergotamine prior to brand name products

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.